---
layout: post
title: "Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:01:22 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-23791
original_published: 2022-11-02 00:00:00 +0000
significance: 8.00
---

# Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** November 02, 2022 00:00 UTC
**Document Number:** 2022-23791

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program." This guidance provides stakeholders with information regarding FDA's implementation of the Over-the-Counter Monograph Drug User Fee Program authorized under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/11/02/2022-23791/assessing-user-fees-under-the-over-the-counter-monograph-drug-user-fee-program-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-23791

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
